Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
p27 as a Transcriptional Regulator: New Roles in Development and Cancer
Seyedeh Fatemeh Razavipour1, Kuzhuvelil B Harikumar2, Joyce M Slingerland3
1Breast Cancer Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC.
Abstract:
p27 binds and inhibits cyclin-CDK to arrest the cell cycle. p27 also regulates other processes including cell migration and development independent of its cyclin-dependent kinase (CDK) inhibitory action. p27 is an atypical tumor suppressor-deletion or mutational inactivation of the gene encoding p27, CDKN1B, is rare in human cancers. p27 is rarely fully lost in cancers because it can play both tumor suppressive and oncogenic roles. Until recently, the paradigm was that oncogenic deregulation results from either loss of growth restraint due to excess p27 proteolysis or from an oncogenic gain of function through PI3K-mediated C-terminal p27 phosphorylation, which disrupts the cytoskeleton to increase cell motility and metastasis. In cancers, C-terminal phosphorylation alters p27 protein-protein interactions and shifts p27 from CDK inhibitor to oncogene. Recent data indicate p27 regulates transcription and acts as a transcriptional coregulator of cJun. C-terminal p27 phosphorylation increases p27-cJun recruitment to and action on target genes to drive oncogenic pathways and repress differentiation programs. This review focuses on noncanonical, CDK-independent functions of p27 in migration, invasion, development, and gene expression, with emphasis on how transcriptional regulation by p27 illuminates its actions in cancer. A better understanding of how p27-associated transcriptional complexes are regulated might identify new therapeutic targets at the interface between differentiation and growth control.
Insights
The protein p27, encoded by CDKN1B, regulates cell cycle, migration, and gene expression. Its noncanonical functions, particularly transcriptional regulation, are crucial in cancer development and progression.
Area of Science:
- Cell Biology
- Molecular Biology
- Oncology
Background:
- The protein p27 (encoded by CDKN1B) is known to inhibit cyclin-CDK complexes, arresting cell cycle progression.
- p27 also influences cell migration and development independently of its cell cycle inhibitory role.
- CDKN1B mutations are rare in cancers, suggesting complex roles for p27 beyond tumor suppression.
Purpose of the Study:
- To review the noncanonical, cyclin-dependent kinase (CDK)-independent functions of p27.
- To emphasize the role of p27 in transcriptional regulation and its implications in cancer.
- To explore how p27's interaction with transcription factors like cJun drives oncogenic pathways.
Main Methods:
- Literature review focusing on CDK-independent functions of p27.
- Analysis of recent data on p27's role in transcription and gene expression.
- Examination of p27's phosphorylation-dependent interactions and their impact on cellular processes.
Main Results:
- p27 acts as a transcriptional coregulator, notably with cJun.
- C-terminal phosphorylation of p27 enhances its interaction with cJun, promoting oncogenic pathways.
- Phosphorylated p27 can repress differentiation programs and drive cancer progression.
- p27's noncanonical functions in migration, invasion, and gene expression are critical in cancer.
Conclusions:
- p27 exhibits dual roles in cancer, acting as both a tumor suppressor and an oncogene.
- Transcriptional regulation by p27, particularly its interaction with cJun, is a key mechanism in cancer.
- Understanding p27-associated transcriptional complexes may reveal new therapeutic targets for cancer treatment.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Master Transcription Regulators
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

